Excision

Excision BioTherapeutics is a clinical-stage biotechnology company developing CRISPR-based in vivo gene-editing therapies aimed at curing serious viral infectious diseases. Its programs apply multiplexed CRISPR editing delivered via AAV vectors to excise viral DNA from the host genome, led by EBT-101, an investigational one-time therapy for HIV. Excision is a therapeutics company with no public developer API, SDK, or documentation surface; this profile is maintained in the API Evangelist network as a venture-portfolio company record rather than an API producer.

Excision is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, CRISPR, Gene Editing, and Therapeutics.

🌐 Visit website 📡 Source on GitHub

7.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyCRISPRGene EditingTherapeuticsLife SciencesInfectious DiseaseVenture Backed

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 7.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/excision: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: excision
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/excision.png
name: Excision
description: Excision BioTherapeutics is a clinical-stage biotechnology company developing CRISPR-based in vivo gene-editing
  therapies aimed at curing serious viral infectious diseases. Its programs apply multiplexed CRISPR editing delivered via
  AAV vectors to excise viral DNA from the host genome, led by EBT-101, an investigational one-time therapy for HIV. Excision
  is a therapeutics company with no public developer API, SDK, or documentation surface; this profile is maintained in the
  API Evangelist network as a venture-portfolio company record rather than an API producer.
url: https://raw.githubusercontent.com/api-evangelist/excision/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- norwest-venture-partners
x-tier: stub
x-tier-reason: therapeutics-company-no-api-surface
x-sector: biotechnology
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- CRISPR
- Gene Editing
- Therapeutics
- Life Sciences
- Infectious Disease
- Venture Backed
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/excision-domain-security.yml
- type: Website
  url: https://excision.bio
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence

Excision

Kin Score

Security Posture 1

Excision Domain Security

Resources

Access & Security 1

Company 1

Source (apis.yml)